In this issue:


1. Share Success: Letters From Readers
2. Research News: Aggressive Hypertension Treatment May Not Help AF
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?

1. Share Success: Letters From Readers 

Letter I: From Hugh M., Columbus, OH

Received at sharesuccess @ ezorbonline.com Apr 29 at 8:04 PM



Subject: Hard fall on basketball court but no breaks, thanks to E-zorb

My name is Hugh M. and I have been taking Ezorb faithfully for about six years. I'm now 86 and have had severe osteoporosis, a herniated disc and lousy bone densities as I recall, due to Celiac Sprue which tends to remove bone calcium, according to the VA.

In addition, 20 years ago I had an attack of Vertigo which left me with a lesser affliction called Labyrinthitis - I'm therefore somewhat unsteady and therefore tend to drift a bit and wobble even though agile.

In January I joined the YMCA with a friend who wanted to lose weight. We'd shoot a little basketball and then go to the gym. On April 17, 2017 the basketball bounced to me so without thinking I took a longer shot and fell on my right hip and shoulder.

With help I got up and hobbled away. Later that day another friend took me to the ER for extensive X-rays of hip and shoulder - NO broken bones or even a crack - just contusions and groin strain. I'll be using a walker for a few weeks.

Thank you Lord for showing mercy, and Ezorb for giving my bones more mass.

Hugh M.

Letter II: From Ruth M.

Received at Testimonial Submit Form Wednesday, December 28, 2016 at 15:01:58



In 2 years my bone density improved 3.2%.

Ruth M.

Letter III: From Beverley F.


Received at Testimonial Submit Form Wednesday, December 28, 2016 at 07:35:46



I have been taking Ezorb since about last May. I have severe osteoporosis. I also have colon cancer. I feel great now.

I gave 1/2 bottle of Ezorb to my choir director to try for her very painful fibromyalgia.

Many thanks and may 2017 be terrific for you!


From the Desk of EZorb Newsletter Editor:

This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. If your testimonial is selected for publication, you will receive a generous gift to show our appreciation of your effort.

2. Research News: Aggressive Hypertension Treatment May Not Help AF


Reducing target blood pressure (BP) does not decrease the incidence of recurrent arrhythmia among patients undergoing catheter ablation for atrial fibrillation (AF), results of a randomized trial suggest.

In the SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial, patients with AF whose BP was greater than 130/80 mmHg at baseline were assigned to receive either aggressive (target BP lt. 120/80 mmHg) or standard (target BP lt. 140/90 mmHg) antihypertensive treatment prior to catheter ablation.

As reported in Circulation, mean BP was significantly lower after a median 3.5 months of aggressive treatment compared with 3.1 months of standard treatment, at 123.2/76.7 mmHg versus 135.4/80.8 mmHg. Baseline measurements were an average of 142.9/84.9 mmHg and 142.2/84.3 mmHg, respectively.

However, there was no significant difference in the rate of recurrent symptomatic AF, atrial tachycardia, or atrial flutter occurring more than 3 months post-ablation between the aggressive and standard treatment groups, with corresponding rates of 61.4% and 61.2%.

The team observed a higher incidence of hypotension requiring medication adjustment among patients receiving aggressive compared with standard BP therapy, at 26.1% versus 0%, and 2.2% of participants in the aggressive treatment group were hospitalized due to effects of the study treatment, compared with none in the standard treatment group.

In prespecified subgroup analyses, the researchers found that recurrent arrhythmia occurred significantly less frequently with aggressive compared with standard treatment among patients aged 61 years and older, but that this was not true among younger patients (55.6 vs 76.9% and 67.4 vs 47.8%, respectively).

"The significance of this finding is uncertain in the context of the globally neutral result," say Ratika Parkash (QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada) and study co-authors. However, they note that there was a larger reduction in BP among patients in the older age group compared with younger participants, which "lends credence to this observation."

Additionally, there was a significant reduction in recurrent arrhythmia with aggressive versus standard treatment in the subgroup of patients with systolic blood pressure of less than 140 mmHg at baseline, but not in those with higher BP.

Therefore, "benefit from aggressive BP treatment may need to begin further upstream, before patients reach the threshold of a high AF symptom burden requiring catheter ablation," the authors suggest.

And the team concludes: "Determining at which point in the atrial substrate pathway where upstream therapy would [reduce] atrial arrhythmia could result in significant benefits to the increasing population of AF patients."

Source: 01-03-2017 / Arrhythmia / News / Article.

3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now



4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.



5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.


    Back to EZorb Newsletter Index

  Copyright 2017 Elixir Industry